Genmab A/S 5/8/2025 Earnings Report

Genmab A/S EPS Results

• Actual EPS: $3.05
• Consensus EPS: $1.88
• Beat/Miss: Beat by +$1.17
• One Year Ago EPS: N/A

Genmab A/S Revenue Results

• Actual Revenue: $765.14 million
• Expected Revenue: $761.09 million
• Beat/Miss: Beat by +$4.05 million
• YoY Revenue Growth: N/A

Genmab A/S Announcement Details

• Date: 5/8/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Genmab A/S (OTCMKTS:GNMSF) is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for cancer and other serious diseases. Founded in 1999 and headquartered in Copenhagen, the company operates research and development facilities across Europe and maintains a global presence through strategic partnerships. Over two decades, Genmab has transitioned from a regional biotech start-up into a fully integrated R&D-driven organization with a focus on advancing novel antibody formats and immuno-oncology solutions.

At the core of Genmab’s innovation is its proprietary antibody platforms, including the DuoBody® bispecific technology and HexaBody® Fc-enhanced platform, which enable the creation of multi-specific and high-potency antibody candidates. The company’s pipeline encompasses a broad array of clinical- and preclinical-stage molecules targeting hematologic malignancies, solid tumors, and autoimmune conditions. Genmab’s collaborative agreements with leading pharmaceutical companies, such as Janssen and Novartis, have yielded several approved therapies, including ofatumumab-based treatments and daratumumab products, underscoring its ability to translate early-stage research into commercially successful medicines.

Genmab serves patients worldwide through its partnerships and sublicensees, with a particular focus on markets in North America, Europe and Asia-Pacific. The company leverages a hybrid model that combines in-house expertise in antibody design, process development and regulatory affairs with the global reach of strategic collaborators. Under the leadership of CEO David L. Junio and an experienced executive team, Genmab continues to expand its pipeline, invest in next-generation antibody technologies and pursue regulatory approvals for novel therapies. This sustained focus on innovation and collaboration positions Genmab as a notable player in the competitive landscape of biopharmaceutical R&D.